Pharnext S.C.A.
6 clinical trials · Sponsor
| Record | Firm | Date |
|---|---|---|
| Phase III Trial Assessing the Efficacy and Safety of PXT3003 in CMT1A Patients (NCT04762758) | Pharnext S.C.A. | 2021-03-30 |
Track Pharnext S.C.A. automatically
Every clearance here is in the API, with alerts when new ones post.